Major functional transcriptome of an inferred center regulator of an ER(-) breast cancer model system

Cancer Informatics

Volumn 11, Issue , 2012, Pages 87-111

  Liu, Li Yu Daisy ^b   Chang, Li Yun ^a   Kuo, Wen Hung ^a   Hwa, Hsiao Lin ^a   Lin, Yi Shing ^c   Huang, Shiu Feng ^d   Chen, Chiung Nien ^a   Chang, King Jen ^a,e   Hsieh, Fon Jou ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Welgene Biotech Co Ltd   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e CHENG CHING GENERAL HOSPITAL   (Taiwan)

Author keywords

Grade; Microarray; STAT3; Transcriptional regulatory network; Vascularity

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FORKHEAD TRANSCRIPTION FACTOR M1; MATRILYSIN; METHIONYL AMINOPEPTIDASE 2; MYC PROTEIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; STAT3 PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; GENE ACTIVITY; GENE EXPRESSION PROFILING; GENE POOL; GENE REGULATORY NETWORK; GENE TARGETING; GENETIC REGULATION; HUMAN; LYMPH NODE; METASTASIS; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; ONCOLOGICAL PARAMETERS; PHENOTYPE; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VASCULARIZATION; WARBURG EFFECT;

EID: 84860790969     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S8633     Document Type: Article

References (54)

1. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol. 2002;32:S66-81.
2. Brown M, Bauer K, Pare M. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004. Breast Cancer Res Treat. 2010;120:217-27.
3. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627-36.
4. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol. 2010;28(16):2777-83.
5. Chang HH, Dreyfuss JM, Ramoni MF. A transcriptional network signature characterizes lung cancer subtypes. Cancer. 2011;117(2):353-60.
6. Liu LYD, Chen CY, Chen MJM, et al. Identification of gene expression relationships by CID to build a transcriptional regulatory network. BMC Bioinformatics. 2009;10:85-97.
7. Watson CJ, Neoh K. The Stat family of transcription factors have diverse roles in mammary gland development. Semin Cell Dev Biol. 2008;19:401-6.
8. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474-88.
9. Frank DA. STAT3 as a central mediator of neoplastic cell transformation. Cancer Lett. 2007;251:199-210.
10. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998;18:2545-52.
11. Hsieh FC, Cheng G, Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun. 2005;335(2): 292-9.
12. Haftchenary S, Avadisian M, Gunning PT. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report. Anti-Cancer Drugs. 2011;22:115-27.
13. Sato T, Neilson LM, Peck AR, et al. Signal transducer and activator of transcription-3 and breast cancer prognosis. Am J Cancer Res. 2011;1(3): 347-55.
14. Barabasi A, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68.
15. Karamouzis MV, Papavassiliou AG. Transcription factor networks as targets for therapeutic intervention of cancer-The breast cancer paradigm. Mol Med. September 6, 2011. doi: 10.2119/molmed.2011.00315.
16. Lien HC, Hsiao YH, Lin YS, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profling: Identification of genes potentially related to epithelial-mesenchymal transition. Oncogene. 2007;26:7859-71.
17. Tsai HY, Hsi BL, Hung IJ, et al. Correlation of MYCN amplification with MCM7 protein expression in neuroblastomas: a chromogenic in situ hybridization study in paraffin sections. Hum Pathol. 2004;35:1397-403.
18. Hou MF, Chuang HY, Ou-Yang F, et al. Comparison of breast mammography, sonography and physical examination for screening women at high risk of breast cancer in Taiwan. Ultrasound Med Biol. 2002;28:415-20.
19. Cheng WF, Lee CN, Chen CA, et al. Comparison between "in vivo" and "in vitro" methods for evaluating tumor angiogenesis using cervical carcinoma as a model. Angiogenesis. 1999;3:295-304.
20. Fleischer AC, Wojcicki WE, Donnelly EF, et al. Quantified color Doppler sonography of tumor vascularity in an animal model. J Ultrasound Med. 1999;18:547-51.
21. Taylor KJW, Ramos I, Carter D, et al. Correlation of Doppler US tumor signals with neovascular morphologic features. Radiology. 1988;166:57-62.
22. Kuo WH, Chang LY, Liu DLY, et al. The interactions between GPR30 and the major biomarkers in infltrating ductal carcinoma of the breast in an Asian population. Taiwan J Obstet Gynecol. 2007;46:135-45.
23. Goldstein DR, Ghosh D, Conlon EM. Statistical issues in the clustering of gene expression data. Stat Sin. 2002;12:219-40.
24. Katagiri F, Glazebrook J. Pattern discovery in expression profling data. Curr Protoc Mol Biol. 2009;Chapter 22: Unit 22.5. 1-22.5.15.
25. Ray PS, Wang J, Qu Y, et al. FOXC1 is a potential prognostic biomarker with functional signifcance in basal-like breast cancer. Cancer Res. 2010;70(10):3870-6.
26. Draper NR, Smith H. Applied Regression Analysis. Wiley Series in Probability and Statistics; 1998.
27. Lee EYHP, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2010;2:a003236.
28. Chabottaux V, Sounni NE, Pennington CJ, et al. Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res. 2006;66(10):5165-72.
29. Blakely CM, Sintasath L, D'Cruz CM, et al. Developmental stage determines the effects of MYC in the mammary epithelium. Development. 2005;132(5):1147-60.
30. Kidder BL, Yang J, Palmer S. Stat3 and c-Myc genome-wide promoter occupancy in embryonic stem cells. PLoS ONE. 2008;3(12):e3932-45.
31. Fuxe J, Vincent T, de Herreros AG. Transcriptional crosstalk between TGF beta and stem cell pathways in tumor cell invasion: Role of EMT promoting Smad complexes. Cell Cycle. 2010;9(12):2363-74.
32. Lin ML, Park JH, Nishidate T, et al. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer Res. 2007;9:R17.
33. Pickard MR, Green AR, Ellis IO, et al. Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res. 2009;11:R60.
34. Hebbard LW, Maurer J, Miller A, et al. Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo. Cancer Res. 2010;70(21):8863-73.
35. Gray D, Jubb AM, Hogue D, et al. Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res. 2005;65(21):9751-61.
36. Simões BM, Piva M, Iriondo O, et al. Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res Treat. 2011;129(1):23-35.
37. Foubert E, Craene BD, Berx G. Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1conspiracy in malignant breast cancer progression. Breast Cancer Res. 2010;12:206-16.
38. Helczynska K, Larsson A, Mengelbier LH, et al. Hypoxia-inducible factor-2 correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res. 2008;68(22):9212-20.
39. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1a and HIF-2a in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157(2):411-21.
40. Maeng YS, Choi HJ, Kwon JY, et al. Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLC2 axis. Blood. 2009;113:233-43.
41. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604-13.
42. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005;24(36):5552-60.
43. Onimaru M, Yonemitsu Y, Fujii T, et al. VEGF-C regulates lymphangiogen-esis and capillary stability by regulation of PDGF-B. Am J Physiol Heart Circ Physiol. 2009;297(5):H1685-96.
44. Bowman T, Broome MA, Sinibaldi D, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. PNAS. 2001;98(13): 7319-524.
45. Selvakumar P, Lakshmikuttyamma A, Das U, Pati HN, Dimmock JR, Sharma RK. NC2213: a novel methionine aminopeptidase 2 inhibitor in human colon cancer HT29 cells. Mol Cancer. 2009;8:65-70.
46. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008;18:254-67.
47. Lee J, Kang WK, Park JO, et al. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS. 2009;117:598-606.
48. Wei D, Le X, Zheng L, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003;22:319-29.
49. Datta B. Roles of P67/MetAP2 as a tumor suppressor. Biochim Biophys Acta. 2009;1796:281-92.
50. Tucker LA, Zhang Q, Sheppard GS, et al. Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation. Oncogene. 2008;27:3967-76.
51. Taube JH, Herschkowitz JI, Komurov K, et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin low and metaplastic breast cancer subtypes. PNAS. 2010;107:15449-54.
52. Riveiro-Falkenbach E, Soengas MS. Control of tumorigenesis and chemore-sistance by the DEK. Clin Cancer Res. 2010;16:2932-8.
53. McGovern UB, Francis RE, Peck B, et al. Geftinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther. 2009;8(3):582-91.
54. Palaskas N, Larson SM, Schultz N, et al. 18F-fuorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 2011;71(15):5164-74.